Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Sept. 24 — Clinical studies to test investigational devices can now be approved by the FDA in about a month, when a few years ago the same process took more than a year, according to a Sept. 24 blog by two of the agency's device leaders.
The blog, “Strengthening the Clinical Trial Enterprise for Medical Devices: An FDA/CDRH Strategic Priority Update,” said that efforts at the Food and Drug Administration to advance the clinical trials program for devices has led to fewer review cycles and shorter overall review times for its investigational device exemptions, which are the authorization to conduct clinical trials on devices to collect safety and effectiveness data. The median number of days to full IDE approval decreased from 442 in 2011 to 101 in 2014, according to the blog. During 2015, the median number of days to full IDE approval has decreased to 30 days, the blog said.
“At the Center for Devices and Radiological Health (CDRH), we are committed to patients having access to high-quality, safe, and effective medical devices—as quickly as possible,” Owen Faris and Jeffrey Shuren wrote. “Innovation is key to both speed and excellence in that endeavor.”
Faris is the acting director of clinical trials in the CDRH's Office of Device Evaluation; Shuren is the director of the CDRH.
They noted the device center identified reducing the time and cost of the clinical trial enterprise in a February 2014 report on strategic priorities.
In addition to shorter review times, Faris and Shuren said, IDE applicants don't have to undergo as many review cycles at the agency. In 2011, they said, 15 percent of IDEs were approved within two review cycles; in 2015, 74 percent of IDEs were approved in two review cycles.
“This performance meets FDA’s strategic goals and, more importantly, means that important technologies have the potential to reach [U.S.] patients,” they said.
There also has been a jump in the CDRH's Early Feasibility Studies (EFS) program, where small clinical studies are designed to gain early insights into an innovative technology during development and before starting a larger clinical trial. They said there has been a 50 percent increase in the number of EFS submissions during the first nine months of 2015, compared with the same period in 2013.
They also highlighted a draft guidance on the benefits and risks for IDE decisions, as well as a draft guidance encouraging the use of adaptive designs for clinical trials and another draft guidance on adaptive clinical trial designs for devices.
“We are committed to making U.S. patients the first in the world to have access to high-quality, safe and effective medical devices,” they said. “We believe these results are clear evidence that we are moving the right direction, helping to ensure that robust and efficient clinical trials that provide appropriate human subject protections take place here in the U.S.”
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Lee Barnes at email@example.com
Shuren and Faris's blog is available at http://blogs.fda.gov/fdavoice/index.php/2015/09/strengthening-the-clinical-trial-enterprise-for-medical-devices-an-fdacdrh-strategic-priority-update/.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)